CompanyHealth
Auxilius Pharma
Auxilius Pharma is a clinical-stage cardiovascular pharmaceutical company developing AUX-001, a once-daily extended-release formulation of nicorandil for the roughly 11 million Americans living with chronic stable angina. By reformulating an established molecule through the FDA's 505(b)(2) pathway, the company aims to deliver what would be the first new innovative oral angina therapy in the US since 2006 - improving adherence, tolerability and outcomes for patients who still suffer symptoms despite optimal treatment.
2019Founded
BostonHQ
$4,000,000Series A
cardiovascularanginachronic stable anginaaux-001nicorandilpharmaceuticals